These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11073272)

  • 1. Management of disturbed calcium metabolism in uraemic patients: 3. Potential perspectives--calcimimetics.
    Schömig M; Ritz E
    Nephrol Dial Transplant; 2000; 15 Suppl 5():30-1. PubMed ID: 11073272
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
    Schömig M; Ritz E
    Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of disturbed calcium metabolism in uraemic patients: 2. Indications for parathyroidectomy.
    Schömig M; Ritz E
    Nephrol Dial Transplant; 2000; 15 Suppl 5():25-9. PubMed ID: 11073271
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of uremic bone disease using calcimimetic compounds.
    Olgaard K; Lewin E
    Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats.
    Chin JI; Miller SC; Wada M; Nagano N; Nemeth EF; Fox J
    J Am Soc Nephrol; 2000 May; 11(5):903-911. PubMed ID: 10770968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
    Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
    J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
    Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
    J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats.
    Fox J; Lowe SH; Conklin RL; Petty BA; Nemeth EF
    J Pharmacol Exp Ther; 1999 Aug; 290(2):480-6. PubMed ID: 10411553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tricking the parathyroid gland with novel calcimimetic agents.
    Nemeth EF; Bennett SA
    Nephrol Dial Transplant; 1998 Aug; 13(8):1923-5. PubMed ID: 9719139
    [No Abstract]   [Full Text] [Related]  

  • 11. [Management of secondary hyperparathyroidism].
    Cunningham J
    Clin Calcium; 2005 Sep; 15 Suppl 1():217-24. PubMed ID: 16279027
    [No Abstract]   [Full Text] [Related]  

  • 12. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium.
    Fox J; Lowe SH; Petty BA; Nemeth EF
    J Pharmacol Exp Ther; 1999 Aug; 290(2):473-9. PubMed ID: 10411552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacology of bone.
    Raisz LG
    Ration Drug Ther; 1971 Jun; 5(6):1-7. PubMed ID: 5565260
    [No Abstract]   [Full Text] [Related]  

  • 14. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.
    Antonsen JE; Sherrard DJ; Andress DL
    Kidney Int; 1998 Jan; 53(1):223-7. PubMed ID: 9453023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis.
    Drüeke TB
    Nephrol Dial Transplant; 2002; 17 Suppl 11():20-2. PubMed ID: 12386252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing for disorders of calcium metabolism.
    Posen S; Clifton-Bligh P; Mason RS
    Pathology; 1980 Oct; 12(4):511-5. PubMed ID: 7465249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The calcium receptor and calcimimetics.
    Wada M; Nagano N; Nemeth EF
    Curr Opin Nephrol Hypertens; 1999 Jul; 8(4):429-33. PubMed ID: 10491737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Parathormone as a uremic toxin. Physiopathological bases and general therapeutic guidelines].
    Brancaccio D; Galmozzi C; Pizzocaro G
    Minerva Med; 1985 Mar; 76(9-10):377-82. PubMed ID: 3982693
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hypercalcemia and hypocalcemia].
    Furukawa Y
    Nihon Naika Gakkai Zasshi; 1992 Sep; 81(9):1384-91. PubMed ID: 1453058
    [No Abstract]   [Full Text] [Related]  

  • 20. The long-term effect of a calcium diet on the bone tissue, C-cells and parathyroid glands of the rat.
    Logonder-Mlinsek M; Pajer Z
    J Endocrinol Invest; 1993 Oct; 16(9):687-90. PubMed ID: 8282964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.